Fulgent Genetics (FLGT)
NASDAQ:FLGT
Want to see FLGT full AI Analyst Report?
Total Valuation
Fulgent Genetics has a market cap or net worth of $493.60M. The enterprise value is $472.70M.
Market Cap$493.60M
Enterprise Value$472.70M
Share Statistics
Fulgent Genetics has 28,400,623 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,400,623
Owned by Insiders38.94%
Owned by Institutions13.66%
Financial Efficiency
Fulgent Genetics’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -7.09%.
Return on Equity (ROE)-0.05
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-7.09%
Return on Capital Employed (ROCE)-0.08
Revenue Per Employee245.75K
Profits Per Employee-46.94K
Employee Count1,313
Asset Turnover0.27
Inventory Turnover18.09
Valuation Ratios
The current PE Ratio of Fulgent Genetics is ―. Fulgent Genetics’s PEG ratio is -0.34.
PE Ratio―
PS Ratio2.51
PB Ratio0.73
Price to Fair Value0.73
Price to FCF-6.51
Price to Operating Cash Flow-5.86
PEG Ratio-0.34
Income Statement
In the last 12 months, Fulgent Genetics had revenue of 322.67M and earned -60.51M in profits. Earnings per share was -1.97.
Revenue322.67M
Gross Profit130.88M
Operating Income-91.10M
Pretax Income-70.03M
Net Income-60.51M
EBITDA-45.83M
Earnings Per Share (EPS)-1.97
Cash Flow
In the last 12 months, operating cash flow was -90.11M and capital expenditures -23.06M, giving a free cash flow of -113.17M billion.
Operating Cash Flow-90.11M
Free Cash Flow-113.17M
Free Cash Flow per Share-3.98
Dividends & Yields
Fulgent Genetics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.45
52-Week Price Change-15.76%
50-Day Moving Average15.78
200-Day Moving Average21.99
Relative Strength Index (RSI)60.89
Average Volume (3m)542.48K
Important Dates
Fulgent Genetics upcoming earnings date is Jul 31, 2026, After Close (Confirmed).
Last Earnings DateMay 1, 2026
Next Earnings DateJul 31, 2026
Ex-Dividend Date―
Financial Position
Fulgent Genetics as a current ratio of 6.48, with Debt / Equity ratio of 0.97%
Current Ratio6.48
Quick Ratio6.35
Debt to Market Cap<0.01
Net Debt to EBITDA0.93
Interest Coverage Ratio-1.21K
Taxes
In the past 12 months, Fulgent Genetics has paid -8.39M in taxes.
Income Tax-8.39M
Effective Tax Rate0.12
Enterprise Valuation
Fulgent Genetics EV to EBITDA ratio is -16.71, with an EV/FCF ratio of -6.17.
EV to Sales2.37
EV to EBITDA-16.71
EV to Free Cash Flow-6.17
EV to Operating Cash Flow-7.54
Balance Sheet
Fulgent Genetics has $276.30M in cash and marketable securities with $10.17M in debt, giving a net cash position of $266.13M billion.
Cash & Marketable Securities$276.30M
Total Debt$10.17M
Net Cash$266.13M
Net Cash Per Share$9.37
Tangible Book Value Per Share$30.81
Margins
Gross margin is 38.71%, with operating margin of -28.23%, and net profit margin of -18.75%.
Gross Margin38.71%
Operating Margin-28.23%
Pretax Margin-21.70%
Net Profit Margin-18.75%
EBITDA Margin-14.20%
EBIT Margin-21.68%
Analyst Forecast
The average price target for Fulgent Genetics is $18.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$18.50
Price Target Upside-19.39% Downside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast9.54%
EPS Growth Forecast-79.16%